secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001437749-23-013644
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q1 revenue up 50.9% YoY to $978K; net loss narrows to $956K
------------------------------------------------------------------

- Revenue of $978K (+50.9% YoY); net loss $(0.03)/share vs $(0.09) prior year.
- Cash and securities $11.8M at Mar 31, 2023, down from $12.7M at Dec 31, 2022.
- Received ~$1.27M from sale of minority stake in Alphazyme in Jan 2023.
- DYAI-100 booster vaccine dosing completed; no serious adverse events; safety report due June 2023.
- Expanded collaborations with Rubic One Health (Africa) and new top-5 pharma research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/0001437749-23-013644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923013644/dyai20230125_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-013644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer